Renal Hyperplasia and Hypertrophy: Role of Cell Cycle Regulatory Proteins

Seldin and Giebisch's The Kidney

Volumn , Issue , 2008, Pages 723-742

  Griffin, Sian V ^a,b   Shankland, Stuart J ^a,b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60449115092     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088488-9.50030-9     Document Type: Chapter

References (264)

1. Abdel Wahab N., Weston B.S., Roberts T., Mason R.M. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 2002, 13:2437-2445.
2. Aktas H., Cai H., Cooper G.M. Ras links growth factor signalling to the cell cycle machinery via regulation of cyclin D1 and the cdk inhibitor p27kip1. Mol Cell Biol 1997, 17:3850-3857.
3. Al-Douahji M., Brugarolas J., Brown P.A.J., et al. The cyclin kinase inhibitor p21Waf1/Cip1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 1999, 56:1691-1699.
4. Atherton-Fessler S., Parker L.L.G.R., Piwnica-Worms H. Mechanisms of p34cdc2 regulation. Mol Cell Biol 1993, 13:1675-1685.
5. Awazu M., Omori S., Ishikura K., Hida M., Fujita H. The lack of cyclin kinase p27Kip1 ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003, 14:699-708.
6. Baker A.J., Mooney A., Lombardi D., Johnson R.J., Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994, 94:2105-2116.
7. Baldin V., Lukas J., Marcote M.J., Pagano M., Draetta G.F. Cyclin D1 is a nuclear protein required for cell cycle progression in G1 cells. Genes Dev 1993, 7:812-821.
8. Barisoni L., Bruggeman L.A., Mundel P., D'Agati V., Klotman P.E. HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 2000, 58:173-181.
9. Barisoni L., Kriz W., Mundel P., D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV associated nephro. J Am Soc Nephrol 1999, 10:51-61.
10. Barisoni L., Mokrzycki M., Sablay L., et al. Podocyte cell cycle regulation and proliferation in collapsing glomerulonephropathies. Kidney Int 2000, 58:137-143.
11. Berthet C., Aleem E., Coppola V., Tessarollo L., Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003, 13:1775-1785.
12. Bhathena D.B. Glomerular basement membrane length to podocyte ratio in human nephronopenia: implications for focal segmental glomerulosclerosis. Am J Kidney Dis 2003, 41:1179-1188.
13. Bloom J., Pagano G. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003, 13:41-47.
14. Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003, 14:555-561.
15. Brandt J., Pippin J., Schulze M., et al. Role of complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 1996, 49:335-343.
16. Brenner B.M. Nephron adaptation to renal injury or ablation. Am J Physiol 1985, 249:F324-F337.
17. Brizzi M.F., Dentelli P., Rosso A., et al. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the develop progression of diabetic nephropathy. FASEB J 2004, 18:1249-1251.
18. Bruggeman L.A., Dikman S., Meng C., et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997, 100:84-92.
19. Bunz F., Dutriaux A., Lengauer C., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
20. Burns K.D., Harris R.C. Signalling and growth responses of LLC-PK1/CI4 cells transfected with the rabbit AT1 ang II receptor. Am J Physiol 1995, 268:C925-C935.
21. Caspary T., Cleary M.A., Perlman E.J., et al. Oppositely imprinted genes p57Kip2 and Igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev 1999, 13:3115-3124.
22. Chen S., Hoffman B.B., Lee J.S., et al. Cultured tubule cells from TGF b1 null mice exhibit impaired hypertrophy and fibronectin expression in high glucose. Kidney Int 2004, 65:1191-1204.
23. Cheng M., Olivier P., Diehl J.A., et al. The p21cip1 and p27kip1 cdk "inhibitors"' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999, 18:1571-1583.
24. Cheng M., Sexl V., Sherr C.J., Roussel M. Assembly of cyclin D dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). PNAS 1998, 95:1091-1096.
25. Clish C.B., O'Brien J.A., Gronert K., et al. Local and systemic delivery of an aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A 1999, 96:8247-8252.
26. Clurman B.E., Sheaff R.J., Thress K., Groudine M., Roberts J.M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996, 10:1979-1990.
27. Conaldi P.G., Bottelli A., Baj A., et al. Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells. Am J Pathol 2002, 161:53-61.
28. Couser W.G., Johnson R.J. Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994, 23:193-198.
29. Coverley D., Laman H., Laskey R.A. Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 2002, 4:523-528.
30. Cusumano A.M., Bodkin N.L., Hansen B.C., et al. Glomerular hypertrophy is associated with hyperinsulinaemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 2002, 40:1075-1085.
31. Cybulsky A.V., Rennke H.G., Feintzeig I.D., Salant D.J. Complement-induced glomerular epithelial cell injury: role of membrane attack complex in rat membranous nephropathy. J Clin Invest 1986, 77:1096-1107.
32. Dalla Vestra M., Masiero A., Roiter A.M., et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type II diabetes mellitus. Diabetes 2003, 52:1031-1035.
33. Dechow C., Morath C., Lehrke I., et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000, 11:1479-1487.
34. Dechow C., Morath C., Peters J., et al. Effects of all-trans retinoic acid on the renin angiotensin system in rats with experimental nephritis. Am J Physiol Renal Physiol 2001.
35. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder S. Mice lacking p21Cip1/Waf1 undergo normal development but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
36. Detwiler R.K., Falk R.J., Hogan S.L., Jenette J.C. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994, 45:1416-1424.
37. Dickie P., Felser J., Eckhaus M., et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991, 185:109-119.
38. Diehl J.A., Cheng M., Roussel M., Sherr C.J. Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localisation. Genes Dev 1998, 12:3499-3511.
39. Diehl J.A., Zindy F., Sherr C.J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997, 11:957-972.
40. Dimberg A., Bahram F., Karlberg I., et al. Retinoic acid induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation and cMyc and cyclin E and posttranscriptiona upregulation of p27Kip1. Blood 2002, 99:2199-2206.
41. Dulic V., Kaufmn W., Wilson S., et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76:1013-1023.
42. Dulic V., Lees E., Reed S.I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992, 257:1958-1961.
43. Durvasula R.V., Pippin J., Petermann A.T., et al. Sublytic C5b-9 induces DNA damage in podocytes in vitro: a novel response to injury which prevents proliferation. J Am Soc Nephrol 2001, 12:609A.
44. El-Deiry W.S., Tokino Y., Velculescu V.E., et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993, 75:817-825.
45. Elledge S.J., Harper J.W. The role of protein stability in the cell cycle and cancer. Biochim Biophys Acta 1998, 1377:M61-M70.
46. Evans T., Rosenthal T.E., Youngblom J., Distel D., Hunt T. Cyclin: a protein specified by maternal mRNA in seas urchin eggs that is destroyed at each cleavage division. Cell 1983, 33:389-396.
47. Fan Y.-P., Weiss R.H. Exogenous attenuation of p21Waf1/Cip1 decreases mesangial hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol 2004, 15:575-584.
48. Feliers D., Duraisamy S., Faulkner J.L., et al. Activation of renal signalling pathways in db/db mice with type 2 diabetes. Kidney Int 2001, 60:495-504.
49. Feliers D., Frank M.A., Riley D.J. Activation of cyclin D1-CDK4 and CDK4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy. Diabetes 2002, 51:3290-3299.
50. Fero M.L., Rivkin M., Tasch M., et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27kip1-deficient mice. Cell 1996, 85:733-744.
51. Filmus J., Robles A.I., Shi W., et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 1994, 9:3627-3633. (abstract).
52. Fine L.G. The biology of renal hypertrophy. Kidney Int 1986, 29:619-634.
53. Fine L.G., Norman J. Cellular events in renal hypertrophy. Annu Rev Physiol 1989, 51:19-32.
54. Floege J., Eng E., Lindner V., et al. Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis and mitogenecity in mesangial proliferative glomerulonephritis. J Clin Invest 1992, 90:2362-2369.
55. Floege J., Eng E., Young B.A., Couser W.G., Johnson R.J. Heparin suppresses mesangial cel proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 1993, 43:369-388.
56. Floege J., Johnson R.J., Gordon K.L., et al. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 1991, 40:477-488.
57. Fogo A., Hawkins E.P., Berry P.L., et al. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 1990, 38:123.
58. Fogo A., Ichikawa I. Evidence for the central role of glomerular growth promoters in the developement of sclerosis. Semin Nephrol 1989, 9:329-342.
59. Franch H.A. Pathways of proteolysis affecting renal cell growth. Curr Opin Nephrol Hypertens 2002, 11:445-450.
60. Franch H.A., Curtis P.V., Mitch W.E. Mechanisms of renal tubular cell hypertrophy: mitogeninduced suppression of proteolysis. Am J Physiol 1997, 273:C843-C851.
61. Franch H.A. Prei. NH4Cl-induced hypertrophy is mediated by weak base effects and is independent of cell cycle processes. Am J Physiol 1996, 270:C932-C938.
62. Franch H.A., Shay J.W., Alpern R.J., Preiseig P. Involvement of pRB family in TGFb-dependent epithelial cell hypertrophy. J Cell Biol 1995, 129:245-254.
63. Franch H.A., Sooparb S., Du J. A mechanism regulating proteolysis of specific proteins during renal tubular cell growth. J Biol Chem 2001, 276:19126-19131.
64. Franch H.A., Wang X., Sooparb S., Brown N.S., Du J. Phosphatidylinositol 3-kinase activity is required for epidermal growth factor to suppress proteolysis. J Am Soc Nephrol 2002, 13:903-908.
65. Fries J.W., Sandstrom D.J., Meyer T.W., Rennke H.G. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 1989, 60:205-218.
66. Garibotto G., Sofia A., Robaudo C., et al. Kidney protein dynamics and ammoniagenesis in humans with chronic metabolic acidosis. J Am Soc Nephrol 2004, 15:1606-1615.
67. Gesualdo L., Di Paolo S., Ranieri E., Schena F.P. Trapidil inhibits human mesangial cell proliferation: effect on PDGF B-receptor binding and expression. Kidney Int 1994, 46:1002-1009.
68. Gheradi D., D'Agati V., Tearina Chu T.-H., et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004, 15:1212-1222.
69. Gilbert T., Merlet-Benichon C. Retinoids and nephron mass control. Pediatr Nephrol 2000, 14:1137-1144.
70. Gille H., Downward J. Multiple Ras effector pathways contribute to G1 cell cycle progression. J Biol Chem 1999, 274:22033-22040.
71. Griffin S.V., Krofft R., Pippin J., Shankland S.J. Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int 2005, 67:977-986.
72. Gross M.L., El-Shakmak A., Szabo A., et al. ACE inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003, 46:856-868.
73. Gross M.L., Ritz E., Schoof A., et al. Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetic nephropathy. Lab Invest 2004, 84:452-464.
74. Guo Y., Stacey D.W., Hitomi M. Post-transcriptional regulation of cyclin D1 expression during G2 phase. Oncogene 2002, 21:7545-7556.
75. Hagting A., Jackman M., Simpson K., Pines J. Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr Biol 1999, 9:680-689.
76. Hannken T., Schroeder R., Stahl R.A.K., Wolf G. Atrial natriuretic peptide attenuates Ang II-induced hypertrophy of renal tubular cells. Am J Physiol 2001, 281:F81-F90.
77. Hannken T., Schroeder R., Stahl R.A.K., Wolf G. Angiotensin II-mediated expression of p27 (kip1) and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 1998, 54:1923-1933.
78. Hannken T., Schroeder R., Zahner G., Stahl R.A.K., Wolf G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27Kip1: role in angiotensin II- mediated hypertrophy of proximal tubular. J Am Soc Nephrol 2000, 11:1387-1397.
79. Harbour J.W., Dean D.C. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000, 14:2393-2409.
80. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
81. Harper J.W., Adams P.D. Cyclin dependent kinases. Chem Rev 2001, 101:2511-2526.
82. Harris R.C., Haralson M.A., Badr K.F. Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Biochem J 1992, 313:697-710.
83. Hengst L., Reed S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996, 271:1861-1864.
84. Hiromura K., Haseley L.A., Zhang P., et al. Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 2001, 60:2235-2246.
85. Hiromura K., Pippin J., Blonski M.J., Roberts J.M., Shankland S.J. The subcellular localisation of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation. Oncogene 2002, 21:1750-1758.
86. Hiromura K., Pippin J., Fero M.L., Roberts J.M., Shankland S.J. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27kip1. J Clin Invest 1999, 103:597-604.
87. Hishiki T., Shirato I., Takahashi Y., et al. Podocyte injury predicts prognosis in patients with IgA nephropathy using a small amount of renal biopsy tissue. Kidney Blood Press Res 2001, 24:99-104.
88. Hoshi S., Shu Y., Yoshida F., et al. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002, 82:25-35.
89. Hostetter T.H. Progression of renal disease and renal hypertrophy. Annu Rev Physiol 1995, 57:263-278.
90. Hsu S.L., Hsu J.W., Liu M.C., Chen L.Y., Chang C.D. Retinoic acid-mediated G1 arrest is associated with induciotn of p27Kip1 and inhibition of cyclin dependent kinase 3 in human lung squamous carcinoma CH27 cel. Exp Cell Res 2000, 258:322-331.
91. Hua X.H., Newport J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on Cdk2. J Cell Biol 1998, 140:271-281.
92. Hudkins K.L., Gilbertson D.G., Carling M., et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 2004, 15:286-298.
93. Ingram A.J., Ly H., Thai K., Kang M., Scholey J.W. Activation of mesangial cell signaling cascades in response to mechanical strain. Kidney Int 1999, 55:476-485.
94. Johnson R.J. The glomerular response to injury: progression or resolution?. Kidney Int 1994, 45:1769-1782.
95. Johnson R.J., Floege J., Couser W.G., Alpers C.E. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol 1993, 4:119-128.
96. Johnson R.J., Raines E.W., Floege J., et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet derived growth factor. J Exp Med 1993, 175:1413-1416.
97. Kaldis P. The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol Life Sci 1999, 55:284-296.
98. Kang D.-H., Hughes J., Mazzali M., Schreiner G.F., Johnson R.J. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilises renal function. J Am Soc Nephrol 2001, 12:1448-1457.
99. Kang D.-H., Kanellis J., Hugo C., et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002, 13:806-816.
100. Kim Y.-G., Alpers C.E., Brugarolas J., et al. The cyclin kinase inhibitor p21Cip1/Waf1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 1999, 55:2349-2361.
101. Kim Y.-G., Suga S.-I., Kang D.-H., et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000, 58:2390-2399.
102. Kitagawa M., Higashi H., Jung H.K., et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996, 15:7060-7069.
103. Klahr S., Schreiner G., Ichikawa I. Progression in renal disease. N Engl J Med 1988, 318:1666.
104. Koepp D.M., Harper J.W., Elledge S.J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999, 97:431-434.
105. Koff A., Giordano A., Desai D., et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992, 257:1689-1694.
106. Kopp J.B., Factor V.M., Mozes M., et al. Transgenic mice with increased plasma levels of TGFbeta 1 develop progressive renal disease. Lab Invest 1996, 74:991-1003.
107. Krek W., Nigg E.A. Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S nd G2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J 1991, 10:305-316.
108. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002, 57:189-195.
109. Kriz W., Gretz N., Lemley K.V. Progression of glomerular diseases: is the podocyte the culprit?. Kidney Int 1998, 54:687-697.
110. Kriz W., Lemley K.V. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999, 8:489-497.
111. Krude T., Jackman M., Pines J., Laskey RA. Cyclin/cdk-dependent initiation of DNA replication in a human cell-free system. Cell 1997, 88:109-119.
112. Kuan C.-J., Al-Douahji M., Shankland S.J. The cyclin kinase inhibitor p21waf1,cip1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 1998, 9:986-993.
113. Kurtz I. Role of ammonia in the induction of renal hypertrophy. Am J Kidney Dis 1991, 17:650-653.
114. LaBaer J., Garrett M., Stevenson L., et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997, 11:847-862.
115. Lee M.-H., Reynisdottir I., Massague J. Cloning of p57Kip2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995, 9:639-649.
116. Lemley K.V., Lafayette R.A., Safai M., et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002, 61:1475-1485.
117. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Med 2001, 2:612-619.
118. Li J., Meyer A.N., Donoghue D.J. Requirement for phosphorylation of cyclin B1 for Xenopus oocyte maturation. Mol Cell Biol 1995, 6:1111-1124.
119. Ling H., Vamvakas S., Gekle M., et al. Role of lysosomal cathepsin activities in cell hypertrophy induced by NH4Cl in cultured renal proximal tubule cells. J Am Soc Nephrol 1996, 7:73-80.
120. Liu B., Preiseig P. TGFb-mediated hypertrophy in rat renal epithelial cells involves inhibiting pRb phosphorylation by preventing activation of cdk2/cyclin E kinase. Am J Physiol 1999, 277:F186-F194.
121. Liu B., Preisig P. Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism. Kidney Int 2002, 62:1650-1658.
122. Liu B., Preisig P. Renal hypertrophy following uninephrectomy is associated with the activation of Cdk2/cyclin E, but not Cdk4/cyclin D1 kinase. J Am Soc Nephrol 1997, 8:424A.
123. Liu B.C., Sun J., Chen Q., et al. Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 2003, 23:429-437.
124. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-CDK complexes. Mol Biol Cell 1998, 18:753-761.
125. Mackay K., Striker L.J., Stauffer J.W., et al. Transforming growth factor beta. Murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest 1989, 83:1160-1167.
126. Marill J., Idres N., Capron C.E., Nguyen E., Chabot G.G. Retinoic acid metabolism and mechanism of action. Curr Drug Metab 2003, 4:1-10.
127. Masuda Y., Shimizu A., Mori T., et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Path 2001, 159:599-608.
128. Matsuoka S., Edwards M.C., Bai C., et al. p57Kip2, a structurally distinct member of the p21Cip1 CDK inhbitor family, is a candidate tumour suppressor gene. Genes Dev 1995, 9:650-662.
129. Matsusaka T., Xin J., Niwa S., et al. Genetic engineering of glomerular sclerosis in the mouse via onset and severity controlled podocyte-specific injury. J Am Soc Nephrol 2005, 16:1013-1023.
130. Matsushime H., Quelle D.E., Shurtleff S.A., et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994, 14:2066-2076.
131. Matsushime H., Roussel M.F., Ashmun R.A., Sherr C.J. Colony-stimulating factor-1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991, 65:701-705.
132. Matsuura I., Denissova N.G., Wang G., et al. Cyclin-dependent kinases regulate the antiproliferative effects of Smads. Nature 2004, 430:226-231.
133. McGowan T.A., McCue P., Sharma K. Diabetic nephropathy. Clin Lab Med 2001, 21:111-146.
134. McMahon B.M., Mitchell S., Brady H.R., Godson C. Lipoxins: revelations on resolution. Trends Pharmacol Sci 2001, 22:391-395.
135. Megyesi J., Price P., Tamayo E., Safirstein R.L. The lack of a functional p21Waf1/Cip1 gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci U S A 1999, 96:10830-10835.
136. Megyesi J., Safirstein R., Price P.M. Induction of p21Waf1/Cip1/Sdi1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998, 101:777-782.
137. Megyesi J., Udvarhelyi N., Safirstein R., Price P.M. The p53-independent activation of transcription of p21Waf1/Cip1/Sdi1 after acute renal failure. Am J Physiol 1996, 271:F1211-F1216.
138. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
139. Mitchell D., Rodgers K., Hanly J., et al. Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am J Pathol 2004, 164:937-946.
140. Mitra J., Enders G.H. Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc2 phosphatases in human cells. Oncogene 2004, 23:3361-3367.
141. Moeller M.J., Soofi A., Hartmann I., et al. Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004, 15:61-67.
142. Monkawa T., Hiromura K., Wolf G., Shankland SJ. The hypertrophic effect of TGF beta is reduced in the absence of the cyclin dependent kinase inhibitors p21 and p27. J Am Soc Nephrol 2002, 13:1172-1178.
143. Morath C., Dechow C., Lehrke I., et al. Effects of retinoids on the TGFb system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 2001, 12:2300-2309.
144. Muda A.O., Feriozzi S., Cinotti G.A., Faraggiana T. Glomerular hypertrophy and chronic renal failure in focal segmental glomerulosclerosis. Am J Kidney Dis 1994, 23:237-241.
145. Nagata M., Nakayama K., Terada Y., Hoshi S., Watanabe N. Cell cycle regulation and differentiation in the human podocyte lineage. Am J Kidney Dis 1998, 153:1511-1520.
146. Nagata M., Tomari S., Kanemoto K., Usui J., Lemley K.V. Podocytes, parietal cells and glomerular pathology: the role of cell cycle proteins. Pediatr Nephrol 2003, 18:3-8.
147. Nakamura T., Ushiyama C., Hara M., et al. Comparative effects of plasma exchange and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis. Clin Nephrol 2002, 57:108-113.
148. Nakayama K., Ishida N., Shirane M., et al. Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumours. Cell 1996, 85:707-720.
149. Nakayama K.-I., Nakayama K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Bioessays 1998, 20:1020-1029.
150. Nath K.A., Hostetter M.K., Hostetter T.H. Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis 1991, 17:654-657.
151. Nelson P.J., Sunamoto M., Husain M., Gelman I.H. HIV-1 expression induces cyclin D1 expression and pRb phosphorylation in infected podocytes: cell-cycle mechanisms contributing to the proliferative phenotype HIV-associated nephropathy. BMC Microbiology 2002, 2:26.
152. National Institute of Diabetic and Digestive and Kidney Disease U.S. Renal Data System, USRDS 2001 annual data report. Atlas of End-Stage Renal Diseases in the United States 2002, National Institutes of Health, Bethesda, MD.
153. Nilsson I., Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 2000, 4:107-114.
154. Noda A., Ning Y., Venable S.F., Pereira-Smith O.M., Smith J.R. Cloning of senescent cellderived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994, 211:90-98.
155. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000, 100:71-78.
156. Ohse T., Ota T., Kieran N., et al. Modulation of interferon-induced genes by lipoxin analogue in anti-GBM nephritis. J Am Soc Nephrol 2004, 15:919-927.
157. Olbricht C.J., Geissinger E. Renal hypertrophy in streptozotocin diabetic rats: role of proteolytic lysosomal enzymes. Kidney Int 1992, 41:966-972.
158. Ophascharoensuk V., Fero M.L., Hughes J., Roberts J.M., Shankland S.J. The cyclin-dependent kinase inhbitor p27kip1 safeguards against inflammatory injury. Nat Med 1998, 4:575-580.
159. Ophascharoensuk V., Pippin J., Gordon K.L., et al. Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney Int 1998, 54:416-425.
160. Ortega S., Prieto I., Odajima J., et al. Cyclin dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003, 35:25-31.
161. Pagano M., Tam S.W., Theodoras A.M., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 1995, 269:682-685.
162. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
163. Papayianni A., Serhan C.N., Phillips M.L., Rennke H.G., Brady H.R. Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 1995, 47:1295-1302.
164. Park S.K., Kang M.J., Kim W., Koh G.Y. Renal tubule regeneration after ischaemic injury is coupled to the up-regulation and activation of cyclins and cyclin dependent kinases. Kidney Int 1997, 52:706-714.
165. Park S.K., Kang S.K., Lee D.Y., et al. Temporal expressions of cyclins and cyclin dependent kinases during renal development and compensatory growth. Kidney Int 1997, 51:762-769.
166. Parker L.L., Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257:1955-1957.
167. Parker S., Eichele G., Zhang P., et al. p53-independent expression of p21Cip1 in muscle and other terminal differentiating cells. Science 1995, 267:1024-1027.
168. Parry D., Mahony D., Wills K., Lees E. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 1999, 19:1775-1783.
169. Peeper D.S., Upton T.M., Ladha M.H., et al. Ras signalling linked to the cell cycle machinery by the retinoblastoma protein. Nature 1997, 386:177-181.
170. Pesce C.M., Striker L.J., Peten E., Elliott S.J., Striker G.E. Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic for growth hormone. Lab Invest 1991, 65:601-605.
171. Petermann A.T., Hiromura K., Blonski M.J., et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002, 61:40-50.
172. Petermann A.T., Pippin J., Durvasula R., et al. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005, 67:157-166.
173. Petermann A.T., Pippin J., Hiromura K., et al. Mitotic cell cycle proteins increase in podocytes despite lack of proliferation. Kidney Int 2003, 63:113-122.
174. Petermann A.T., Pippin J., Krofft R., et al. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulsclerosis. Nephron Exp Nephrol 2004, 98:e114-e123.
175. Pines J. Cyclins and cyclin dependent kinases: a biochemical view. Biochem J 1995, 308:697-711.
176. Pippin J., Durvasula R., Petermann A.T., et al. DNA damage is a novel response to sublytic complement C5b-9-induced injury in pododcytes. J Clin Invest 2003, 111:877-885.
177. Pippin J., Qu Q., Meijer L., Shankland S.J. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-depend antagonist. J Clin Invest 1997, 100:2512-2520.
178. Pippin J.W., Durvasula R.V., Petermann A.T., et al. Podocytes exhibit DNA damage in vivo in experimental membranous nephropathy. J Am Soc Nephrol 2001, 12:638A.
179. Polyak K., Lee M.-H., Erdjument-Bromage H., et al. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potent mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66.
180. Preiseig P. What makes cells grow larger and how do they do it: hypertrophy revisited. Exp Nephrol 1999, 7:273-283.
181. Preiseig P. A cell cycle-dependent mechanism of renal tubule epithelial cell hypertrophy. Kidney Int 1999, 56:1193-1198.
182. Quelle D.E., Zindy F., Ashman R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000.
183. Rabkin R., Fervenza F.C. Renal hypertrophy and kidney disease in diabetes. Diabetes Metab Rev 1996, 12:217-241.
184. Rennke H.G. How does glomerular epithelial cell injury contribute to glomerular damage?. Kidney Int 1994, S45:S58-S63.
185. Ritz E., Keller C., Bergis K., Strojek K. Pathogenesis and course of renal disease in IDDM/NIDDM: differences and similarities. Am J Hypertens 1997, 10:202S-207S.
186. Roberts A.B., McCune B.K., Sporn M.B. TGF beta: regulation of extracellular matrix. Kidney Int 1992, 41:557-559.
187. Ruef C., Budde K'Lacy J., Nothemann W., et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 1990, 38:249-257.
188. Ruperez M.R., Ruiz-Ortega M., Esteban V., et al. Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003, 163:1937-1947.
189. Ryffel B., Car B.D., Gunn H., et al. Interleukin 6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Path 1994, 144:927-937.
190. Salant D.J., Darby C., Couser W.G. Experimental membranous glomerulonephritis in rats. J Clin Invest 1980, 66:71-81.
191. Savill J. Regulation of glomerular cell number by apoptosis. Kidney Int 1999, 56:1216-1222.
192. Scheurer D. Rapid reversal of renal failure after intiation of HAART: a case report. AIDS Read 2004, 14:443-447.
193. Schoecklmann H.O., Rupprecht H.D., Zauner I., Sterzel R.B. TGF-beta1 induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-CDK2 activation and retinoblastoma protein phosphorylation. Kidney Int 1996, 51:1228-1236.
194. Schwartz E.J., Cara A., Snoeck H., et al. HIV-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 2001, 12:1677-1684.
195. Schwartz M.M., Evans J., Bain R., Korbet S.M. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 1999, 10:1900-1907.
196. Seewaldt V.L., Dietze E.C., Johnson B.S., Collins S.J., Parker M.B. Retinoic acid mediated G1-S phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression. Cell Growth Differ 1999, 10:49-59.
197. Shankland S.J., Eitner F., Hudkins K.L., et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000, 58:674-683.
198. Shankland S.J., Floege J., Thomas S.E., et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial proliferation in vivo. Kidney Int 1997, 522:404-413.
199. Shankland S.J., Hugo C., Coats S.R., et al. Changes in cell-cycle protein expression during experimental mesangial proliferative nephritis. Kidney Int 1996, 50:1230-1239.
200. Shankland S.J., Johnson R.J. TGF beta in glomerular disease. Miner Electrolyte Metab 1998, 24:168-173.
201. Shankland S.J., Pippin J., Flanagan M., et al. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27kip1. Kidney Int 1997, 51:1088-1099.
202. Shankland S.J., Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation and apoptosis. Am J Physiol 2000, 278:F515-F529.
203. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., Clurman B.E. Cyclin E-cdk2 is a regulator of p27kip1. Genes Dev 1997, 11:1464-1478.
204. Shecter P., Boner G., Rabkin R. Tubular cell protein degradation in early diabetic renal hypertrophy. J Am Soc Nephrol 1994, 4:1582-1587.
205. Shecter P., Shi J.D., Rabkin R. Renal tubular cell protein breakdown in uninephrectomized and ammonium chloride-loaded rats. J Am Soc Nephrol 1994, 5:1201-1207.
206. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001, 2:731-737.
207. Sherr C.J. Mammalian G1 cyclins. Cell 1993, 73:1065.
208. Sherr C.J. Parsing Ink4a/Arf: "pure" p16-null mice. Cell 2001, 106:531-534.
209. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin dependent kinases. Genes Dev 2005, 18:2699-2711.
210. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1 phase progression. Genes Dev 1999, 13:1501-1512.
211. Smits V.A.J., Klompmaker R., Vallenius T., Rijksen G., Makela T.P. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 2000, 275:30638-30643.
212. Smits V.A.J., Medema R.H. Checking out the G2/M transition. Biochim Biophys Acta 2001, 1519:1-12.
213. Sooparb S., Price S.R., Shaoguang J., Franch H.A. Suppression of chaperone-mediated autophagy in the renal cortex during acute diabetes mellitus. Kidney Int 2004, 65:2135-2144.
214. Striker L.J., Doi T., Elliott S.J., Striker G.E. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 1989, 9:318-328.
215. Suzuki A., Ito T., Imai E., et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003, 14:981-991.
216. Takahashi K., Nakayama K.-I., Nakayama K. Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem 2000, 127:73-83.
217. Tenschert S., Elger M., Lemley K.V. Glomerular hypertrophy after subtotal nephrectomy: relationship to early glomerular injury. Virchows Arch 1995, 426:517.
218. Tollins J.P., Hostetter M.K., Hostetter T.H. Hypokalemic nephropathy in the rat: role of ammonia in chronic tubular injury. J Clin Invest 1987, 79:1447-1458.
219. Toth T., Takebayashi S. Glomerular hypertrophy in relapsing minimal change nephropathy. Nephron 1996, 74:64-71.
220. Tovbin D., Franch H.A., Alpern R.J., Preisig PA. Media acidification inibits TGFb-mediated growth suppression in cultured rabbit proximal tubule cells. Proc Assoc Am Physicians 1997, 109:572-579.
221. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74.
222. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002, 3:11-20.
223. Tsuboi Y., Shankland S.J., Grande J.P., et al. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibition of cAMP phosphodiesterase isoenzymes types III and IV. J Clin Invest 1996, 98:262-270.
224. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclindependent kinase inhibitor p27Kip1. EMBO J 1997, 16:5334-5344.
225. Walsh-Reitz M.M., Toback F.G. Kidney epithelial cell growth is stimulated by lowering extracellular potassium concentration. Am J Physiol 1983, 244:C429-C432.
226. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
227. Weir M.R. Diabetes and hypertension: blood pressure control and consequences. Am J Hyperten 1999, 12:170S-178S.
228. Welcker M., Singer J.D., Loeb K.R., et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003, 12:381-392.
229. White K.E., Bilous R.W. Estimation of podocyte number: a comparison of methods. Kidney Int 2004, 66:663-667.
230. White K.E., Bilous R.W. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004, 19:1437-1440.
231. White K.E., Bilous R.W., Marshall S.M., et al. Podocyte number in normotensive type I diabetic patients with albuminuria. Diabetes 2002, 51:3083-3089.
232. Winston J.T., Coats S.R., Wang Y.-Z., Pledger W.J. Regulation of the cell cycle machinery by oncogenic Ras. Oncogene 1996, 12:127-134.
233. Wolf G. Changing concepts of compensatory renal growth: from humoral pathology to molecular biology. Am J Nephrol 1992, 12:369-373.
234. Wolf G. Molecular mechanisms of renal hypertrophy: role of p27Kip1. Kidney Int 1999, 56:1262-1265.
235. Wolf G. Cellular mechanisms of tubule hypertrophy and hyperplasia in renal injury. Miner Electrolyte Metab 1995, 21:303-316.
236. Wolf G., Jablonski K., Schroeder R., et al. Angiotensin II-induced hypertrophy of proximal tubular cells requires p27Kip1. Kidney Int 2003, 64:71-81.
237. Wolf G., Kuncio G.S., Sun M.J., Neilson E.G. Expression of homeobox genes in a proximal tubule cell line derived from adult mice. Kidney Int 1991, 39:1027-1033.
238. Wolf G., Mueller E., Stahl R.A.K., Ziyadeh F.N. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor beta. J Clin Invest 1993, 92:1366-1372.
239. Wolf G., Neilson E.G. Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int 1991, 39:401-420.
240. Wolf G., Neilson E.G. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol Renal Fluid Electrolyte Physiol 1990, 259:F768-F777.
241. Wolf G., Reinking R., Zahner G., Stahl R.A.K., Shankland S.J. Erk 1,2 phosphorylates p27Kip1: functional evidence for a role in high glucose-induced hypertrophy of mesangial cells. Diabetologica 2003, 46:1090-1099.
242. Wolf G., Schroeder R., Thaiss F., et al. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycaemia. Kidney Int 1998, 53:869-879.
243. Wolf G., Schroeder R., Zahner G., Stahl R.A.K., Shankland S.J. High glucose-induced hypertrophy of mesangial cells requires p27Kip1, an inhibitor of cyclin dependent kinases. Am J Path 2001, 158:1091-1100.
244. Wolf G., Schroeder R., Ziyadeh F.N., et al. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells. Am J Physiol 1997, 42:F348-F356.
245. Wolf G., Sharma K., Chen Y., Ericksen M., Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF beta. Kidney Int 1992, 42:647-656.
246. Wolf G., Stahl R.A.K. Angiotensin II-stimulated hypertrophy of LLC-PK1 cells depends on the induction of the cyclin dependent kinase inhibitor p27Kip1. Kidney Int 1996, 50:2112-2119.
247. Wolf G., Wengel U., Ziyadeh F.N., Stahl R.A.K. Angiotensin converting enzyme inhibitor treatment reduces glomeular p16INK4a and p27Kip1 expression in diabetic BBdp rats. Diabetologica 1999, 42:1425-1432.
248. Wolf G., Wenzel U., Hannken T., Stahl R.A.K. Angiotensin II induces p27Kip1 expression in renal tubules in vivo: role of reactive oxygen species. J Mol Med 2001, 79:383-389.
249. Wolf G., Ziyadeh F.N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999, 56:393-405.
250. Won K.-A., Reed S.I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 1996, 15:4182-4193.
251. Xiong Y., Hannon G.J., Zhang H., et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
252. Xu Q., Lucio-Cazana F.J., Kitamura M., et al. Retinoids in nephrology: promises and pitfalls. Kidney Int 2004, 66:2119-2131.
253. Xu Z.G., Yoo T.H., Ryu D.R., et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose stimulated podocytes and in diabetic glomeruli. Kidney Int 2005, 67:944-952.
254. Yamamoto T., Wilson C.B. Complement dependence of antibody-induced mesangial cell injury in the rat. J Immunol 1987, 138:3758-3765.
255. Yamamoto T., Wilson C.B. Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int 1987, 32:514-525.
256. Yan Y., Frisen J., Lee M.-H., Massaque J., Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997, 11:973-983.
257. Yanagita M. The role of the vitamin K-dependent growth factor Gas6 in glomerular pathophysiology. Curr Opin Nephrol Hypertens 2004, 13:465-470.
258. Yang J., Bardes E.S.G., Moore J.D., et al. Control of cyclin B1 localisation through regulated binding of the nuclear export factor CRM1. Genes Dev 2002, 12:2131-2143.
259. Young B.A., Johnson R.J., Alpers C.E., et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995, 47:935-944.
260. Yu Q., Sicinski P. Mammalian cell cycles without cyclin E-CDK2. Cell Cycle 2004, 3:292-295.
261. Zatz R., Fujuhara C.K. Glomerular hypertrophy and progressive glomerulopathy: is there a definitive pathogenetic correlation?. Kidney Int 1994, 45:S27-S29.
262. Zhang P., Liegeois N.J., Wong C., et al. Altered cell differentiation and proliferation in mice lacking p57Kip2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997, 387:151-158.
263. Ziyadeh F.N., Sharma K. Role of transforming growth factor b in diabetic glomerulosclerosis and renal hypertrophy. Kidney Int 1995, 48:S34-S36.
264. Ziyadeh F.N., Sharma K., Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming gr. J Clin Invest 1994, 93:536-554.